Solid Biosciences vs Scholar Rock
SLDB and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SLDB and SRRK compare
Scholar Rock is the larger company, worth 8.2 times as much as Solid Biosciences ($5.5B against $668M).
Solid Biosciences scores higher on the StockData Score (7 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SLDB | SRRK |
|---|---|---|
| Size and price | ||
| Market cap | $668M | $5.5B |
| Share price | $6.23 | $45.08 |
| Change, 1 year | 46.9% | 20.5% |
| Change, 5 years | −77.8% | 67.1% |
| Beta (5Y) | 1.46 | 0.83 |
| Employees | 121 | 289 |
| StockData Score | ||
| Total score | 7 (better) | 2 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.8× (better) | 21.6× |
| FCF yield | −23.6% | −5.4% (better) |
| Profitability | ||
| Return on equity | – | −168% |
| Financial health | ||
| Debt / equity | 0.00 | 0.77 (better) |
| Interest coverage | – | −38.0× |
| Current ratio | 13.82 (better) | 7.02 |
| Altman Z-score | 4.70 | 6.59 (better) |
| Piotroski F-score | – | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −4.6% |
| Shareholder yield | 0.00% (better) | −4.6% |
| Ownership | ||
| Held by institutions | 107% | 114% |
| Held by insiders | 26.7% | 28.9% |
| Insider net buying, 12 months | −$2.7M (better) | −$7.4M |
| Short interest, % of float | 16.9% | 27.1% |
Go deeper
- SLDB stock overview
- SLDB income statement
- SLDB valuation and score
- SRRK stock overview
- SRRK income statement
- SRRK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.